Difference between revisions of "CT Angiography Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 10: Line 10:
*[[Media: 2020 06 16 QIBA CT Angiography_FINAL.pdf | June 16, 2020]]
*[[Media: 2020 06 16 QIBA CT Angiography_FINAL.pdf | June 16, 2020]]
*[[Media: 2020 04 24 QIBA CT Angiography_FINAL.pdf | April 24, 2020]]
*[[Media: 2019 11 12 QIBA CT Angiography_SME_FINAL-2.pdf | November 12, 2019 (SME call)]]
'''''[[CT Angiography Call Summaries Archive]]'''''
'''''[[CT Angiography Call Summaries Archive]]'''''

Revision as of 16:13, 21 January 2022

Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT

RSNA Staff Support: Julie Lisiecki


Recent Call Summaries:

CT Angiography Call Summaries Archive

Project Snapshot - CT Angiography

The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).

Excerpt from the biomarker committee submission form:

The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.

Profile Development

Atherosclerosis Biomarkers Profile Draft Archive

Groundwork Projects

Reference Materials

Conformance Materials